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BENZOFURAN DERIVATIVES SUBSTITUTE FOR THE DISCRIMINATIVE STIMULUS
EFFECTS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) IN MALE
SPRAGUE-DAWLEY RATS
Candace Johnson, M.A.
Western Michigan University, 2022
3, 4-Methylenedioxymethamphetamine (MDMA) is currently under evaluation in phase
III clinical trials as medication-assisted therapy for post-traumatic stress disorder (PTSD) and is
expected to be approved by the FDA for clinical use in the near future. MDMA is also a popular
abused substance with risks for cardiovascular toxicity and neurotoxicity, particularly when
misused at higher doses. Characterization of the behavioral and neurochemical effects of novel
psychoactive substances is an essential step in the development of safer alternative therapeutic
agents. Drug discrimination is a preclinical behavioral assay with pharmacological specificity for
characterizing in vivo drug actions in the central nervous system. This study implemented rodent
drug discrimination to characterize the enantiomers of 5-(2-methylaminopropyl) benzofuran
(5MAPB), 5-(2- methylaminobutyl) benzofuran (5-MBPB), and 6-(2- methylaminobutyl)
benzofuran, benzofuran derivatives with potential MDMA-like effects. Eight male Sprague
Dawley rats were trained in a standard two-lever operant drug discrimination procedure under a
fixed ratio 20 schedule of food reinforcement to discriminate MDMA (1.5 mg/kg) from saline.
Once criteria for stimulus control were established, stimulus substitution tests were conducted
with (RS) 5-MAPB, (R)-5-MAPB, (S)-5-MAPB, (R)-5-MBPB, (S)-5-MBPB, (R)-6-MBPB, and
(S)-6-MBPB. All substances produced dose-dependent increases in MDMA-lever responding
and full substitution at the highest dose assessed with minimal effects on response rate. The Sand R- enantiomers differed slightly in potency. These findings, considered together with in vitro
neurochemical assays, indicate the benzofuran scaffold is a viable candidate for development of
medications with MDMA-like therapeutic effects and reduced toxicities.
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INTRODUCTION
3,4-methylenedioxymethamphetamine (MDMA), commonly known as “Molly” or
“Ecstasy” among recreational users, is a phenethylamine derivative with structural similarities to
the psychostimulant, methamphetamine and the hallucinogen, mescaline (Luethi & Liechti,
2018). The S (+) isomer of MDMA produces psychostimulant and empathogenic effects and the
R (-) isomer exerts hallucinogenic effects (Kalant, 2001; Luethi & Liechti, 2018). MDMA
inhibits reuptake and stimulates the release of serotonin (5-HT), dopamine (DA), and
norepinephrine (NE). These monoamine neurotransmitters have been implicated in mood
disorders and anxiety, and the therapeutic potential of MDMA has been a topic of interest for
several decades (Parrott, 2007; Pentney, 2001).
Recently, MDMA-assisted psychotherapy has received considerable attention, and phase
III clinical trials are ongoing for the treatment of post-traumatic stress disorder (PTSD).
Individuals with PTSD have intrusive memories from a traumatic event, which invokes physical
and emotional reactions, flashbacks, and negative thinking (Boeckel et al., 2017). The
empathogenic and pro-social effects of MDMA reduce anxiety and facilitate conversation,
which helps patients describe traumatic experiences (Carhart-Harris et al., 2014; Boeckel et al.,
2017). In phase II clinical trials, symptom alleviation was assessed through the clinician
administered PTSD scale (CAPS-IV). Results from two different studies indicate that PTSD
symptom severity significantly decreased following MDMA assisted-psychotherapy (Jerome et
al., 2020; Mithoefer et al., 2018).
Though preliminary results from clinical trials with MDMA are promising, there remain
causes for concern. Recreational MDMA use has a well-documented history of neurotoxicity
and cardiovascular issues (Mitchell et al., 2021; Simmler & Liechti, 2018). Both acute and
chronic
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MDMA use has negative consequences. Prolonged MDMA use results in depleted 5-HT receptor
density, widespread 5-HT depletion in the cerebral cortex, and potential serotonergic
neurotoxicity (Parrott, 2013). Neuroimaging studies in humans have also shown decreases in
5HT density in heavy MDMA users (Aguilar et al., 2020; Kish et al., 2000; Reneman et al.,
2006).
Similarly, single, low doses of MDMA can produce serotonergic deficits as well (Mueller et al.,
2013). Fluctuations in serotonergic functioning impacts cell activity, sleep, mood, and memory
(Parrott, 2013). MDMA use can also lead to cardiovascular toxicity due to overstimulation of
noradrenergic receptors (Simmler & Liechti, 2018). These harmful side effects of MDMA
highlight the need for a similar but safer therapeutic alternative. Novel psychoactive substances
(NPS) such as benzofurans are structurally similar to MDMA and can be explored as a medicinal
option. Additionally, subjective reports detail similar hallucinogen and empathogenic effects
following benzofuran use (Greene, 2013).
To further examine structure activity relationships between benzofuran derivatives and
MDMA, this study employed the drug discrimination procedure. Drug discrimination is a well
regarded in vivo preclinical behavioral assay that elucidates the neurochemical actions of novel
and well known compounds. This paradigm has predictive utility and is often used to schedule
the risk and abuse potential of drugs (Gauvin et al., 2018; Glennon & Young, 2011; Horton et al.,
2013). The U.S. Food & Drug Administration has used drug discrimination studies to inform
scheduling of drugs such as Lisdexamfetamine (Vyvanse) and Briveracetam (Briviact) (Gauvin
et al., 2018). Through several drug discrimination experiments, Schechter (1987;1988)
demonstrated that the interoceptive stimulus effects of MDMA are mediated through
serotonergic and dopaminergic pathways. Using rats trained to discriminate MDMA, Harvey &
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Baker (2016) determined that 5-HT release was a crucial aspect of mephedrone’s stimulus
effects. Moreover, Simmler & Lietchi (2018) concluded that MDMA-like NPSs have a low
abuse liability based on their high selectivity for serotonin receptor transporters (SERT) and
norepinephrine receptor transporters (NET) instead of dopamine receptor transporters (DAT).
Taken together, drug discrimination is a trusted and useful paradigm to determine the mechanism
of action and salient features of novel MDMA-like substances (Berquist et al., 2020; Schetcher,
1988).
Previous studies have assessed the pharmacology of (RS)-5-MAPB and its metabolite (5APB) (Dolan et al., 2017; Fuwa et al., 2016; Shimshoni et al., 2017; Simmler & Lietchi, 2018).
An in vivo microdialysis study in mouse striatum demonstrated that 5-MAPB increased
extracellular concentrations of NE, 5-HT, and DA to a significantly greater extent in comparison
to MDMA (Fuwa et al., 2016). Additionally, 5-MAPB is an agonist at 5-HT1A, 5-HT2A and
5HT2C receptor sites (Rickli et al., 2015; Shimshoni et al., 2017; Oeri et al., 2021). To date, few
published studies have evaluated benzofurans in the drug discrimination paradigm. Dolan et al.
(2017) demonstrated that 4-APB and 6-APDB substituted fully in rats trained to discriminate
MDMA. Whereas pharmacological specificity is a key strength of nonhuman drug
discrimination, the aim of the present study is to characterize the (S)- and (R)- enantiomers of of
three benzofuran derivatives, 5-MAPB, 6-MBPB, and 5-MBPB, for substitution in rats trained to
discriminate MDMA. Based on the aforementioned findings reported by Dolan et al. (2017), it
was predicted that these substances would fully substitute for MDMA.

METHODS
Subjects: Eight adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA)
were individually housed in polycarbonate cages with corncob bedding in animal facilities
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maintained at a constant temperature of (20 ± 2 °C) and humidity (50 ± 5%) and under a 12:12
light/dark cycle (lights on from 07:00 to 19:00 h). Animals were provided water ad libitum in
home cages and fed restricted diets of commercial rodent chow (Purina®, Richmond, IN, USA)
to maintain body weights at approximately 90% of free-feeding weights (380-460 g). All
procedures were reviewed and approved by the Western Michigan University Institutional
Animal Care and Use Committee and were in accordance with the guidelines of the Guide for the
Care and Use of Laboratory Animals (National Research Council of the National Academies
2011).
Apparatus: All tests were conducted in eight three-lever, sound-attenuated operant conditioning
chambers (ENV-001, Med Associates Inc., St. Albans, Vermont, USA), and controlled using
Med-PC software (version IV, Med Associates Inc.). Food reinforcers consisted of 45 mg
Dustless Precision Pellets® (Product# F0021, Bio-Serv Inc., Flemington, New Jersey, USA)
dispensed from a pellet dispenser directly above the center lever.
Drugs: 3,4-Methylenedioxymethamphetamine (MDMA) was provided by the National Institute
on Drug Abuse Drug Control Supply Program (Bethesda, MD) 5-(2-methylaminopropyl)
benzofuran, 5-(2-methylaminobutyl) benzofuran, and 6-(2-methylaminobutyl) benzofuran were
supplied by Tactogen (Menlo Park CA). All drugs were dissolved in 0.9% saline and injected
intraperitoneally at a volume of 1 ml/kg. Doses were calculated based on the weight of the solid
compound.
Preliminary Training: Subjects initially completed one 60-minute session to acclimate them to
the operant chambers and food pellet delivery. During this session, no levers were present and
pellets were dispensed on a 60-second fixed time interval. Following this session, rats received
pellets in their home cage to reduce the novelty of the reinforcer. Subsequent training sessions
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lasted 20 minutes and were conducted once per day 5-6 times a week. During preliminary lever
press training, the center lever was extended, and reinforcement was delivered on a fixed ratio
(FR) 1 schedule that was gradually incremented based on subject performance to an FR 20
schedule.
Errorless Training: Once subjects consistently responded on an FR 20 schedule, errorless
training commenced. For these sessions, only one lever was extended during the session (i.e,
center, left, or right lever). Subjects were given an intraperitoneal saline or 1.5 mg/kg of MDMA
injection 15 minutes before each training session. Subjects 1-4 were reinforced for responses on
the left lever following MDMA injections and for responses on the right lever after saline
injections. Conditions were reversed for subjects 5-8. Responses were reinforced on a fixed ratio
schedule that was incremented from FR 1 to FR 20 over 24 (±2) sessions based on subject
performance. Errorless training sessions were conducted with each lever in the following order:
V, V, D, D, V, D.
Discrimination Training: Drug (D) and vehicle (V) training sessions lasted 20 minutes and
followed an alternating schedule of V, V, D, D, V, D. For these sessions, both the left and right
levers were extended. Rats were trained until stimulus control was established. Specifically, they
were required to complete a minimum of eight out of ten consecutive training sessions with 80%
or greater correct lever responses on the first FR and for the remainder of each training session
before substitution testing could begin.
Substitution Testing: Substitution tests were conducted with a range of MDMA doses (0.19,
0.38, 0.75. 1.5 mg/kg) and saline. Test sessions were conducted similar to training sessions, with
the exception that no reinforcers were delivered upon completion 20 consecutive responses on
either lever. Test sessions ended upon completion of an FR 20 or after 20 minutes elapsed,
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whichever occurred first. Before subjects were tested for stimulus generalization with each test
dose, they were required to meet the criteria for stimulus control on at least one V and one D
training session. Both the racemic combination and the (R)- and (S)- enantiomers of 5(2methylaminopropyl) benzofuran (0.15, 0.32, 0.68, and 1.2 mg/kg. I.P. 30 min) were assessed.
Subsequently, (S)- and (R)-5-(2-methylaminobutyl) benzofuran (0.32,0.64,1.28, and 2.56 mg/kg,
I.P. 30 min) were tested. Lastly, (S)- and (R)-6-(2-methylaminobutyl) benzofuran (0.32,
0.64,1.28, 2.56 mg/kg, I.P. 30 min) were assessed for substitution. The results of substitution
tests were used to plot dose response curves for each compound.
Data Analysis: Sessions to criteria were denoted as the number of training sessions completed to
meet stimulus control (criteria: 80% or higher for the minimum of eight out of ten sessions).
Percent drug lever was calculated by dividing the number of responses emitted on the MDMAassociated lever by the total number of responses on both levers and multiplying by 100.
Response rates were expressed as the number of responses emitted per second throughout the test
session. For the dose-response curve, full substitution was considered 80% or greater lever
responses on the MDMA associated lever; partial substitution was defined as responses between
20-79% on the MDMA paired lever; no substitution was 20% or less responses on the MDMA
associated lever. Nonlinear regressions were performed on the percentage MDMA lever dose
response curves to determine ED50s. For each test compound assessed, response rate was
analyzed with a repeated measures analysis of variance. Statistical significance was determined
at alpha of p <0.05. All statistical and graphical analyses were performed using the GraphPad
Prism version 7 software (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
All eight rats met the initial criteria for stimulus control in 34 (± 17.58) training sessions.
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After stimulus control was established with MDMA, substitution tests were conducted with a
range of MDMA doses to generate a dose response curve for comparison to each test compound.
Figure 1 depicts the MDMA dose response curve. As displayed in this figure, MDMA produced
a dose-dependent increase in MDMA-lever responses with full substitution following 0.75 mg/kg
and 1.5 mg/kg. Response rate was not significantly different among MDMA doses or in
comparison to saline control levels [F (4, 28) = 1.03, P=0.41]. The MDMA ED50 was 0.37
(Confidence Intervals (C.I.): 0.27 to 0.49).

Figure 1. Dose response curve for MDMA. Percent MDMA-Lever Responses (closed symbols)
is plotted on the left Y axis and response rate (open symbols) is plotted on the right Y axis.
Points represent group means (± S.E.M.).
Figure 2 depicts the dose response curves generated from substitution tests with racemic
5-MAPB and each of its enantiomers. Each of these compounds produced a dose-dependent
increase in MDMA-lever responses with full substitution following 0.6 mg/kg and 1.2 mg/kg.
Additionally, (R)-5-MAPB was more potent than the other compounds, producing full
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substitution at 0.3 mg/kg. The ED50s for (RS)-5-MAPB, (S)-5-MAPB and (R)-5-MAPB are 0.37
(C.I.: 0.27 to 0.49), 0.28 (C.I.: 0.20 to 0.39), and 0.20 (C.I.: 0.234 to 0.57), respectively.
Response rates were similar following treatment with racemic and (R)- 5-MAPB, while (S)5MAPB produced more variability in response rates following higher doses. Differences in
response rates were not statistically significant following (RS)-5-MAPB [F (4, 28) = 2.41,
P=0.07] or (R)-5-MAPB [F (4, 28) = 1.38, P=0.26]. However, there was a statistically significant
effect of (S)-5-MAPB on response rate [F (4, 28) = 3.04, P=0.03].

Figure 2. Dose response curves for (RS)-5-MAPB, (S)-5-MAPB, and (R)-5-MAPB. Percent
MDMA-Lever Responses (closed symbols) is plotted on the left Y axis and response rate (open
symbols) is plotted on the right Y axis. Points represent group means (± S.E.M.).
The dose response curves generated from substitution tests with the enantiomers of
5MBPB are displayed in figure 3. (S)-5-MBPB produced a dose-dependent increase in MDMA
lever responses with full substitution following 1.28 mg/kg and 2.56 mg/kg. (R)-5-MBPB
produced a dose-dependent increase in MDMA-lever responses with partial substitution at 1.28
mg/kg, and full substitution following 2.56 mg/kg. The ED50s for (S)-5-MBPB and (R)-5MBPB
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are 0.35 (C.I.: 0.02 to 0.62) and 0.74 (C.I.: 0.44 to 1.14), respectively. Both (S)-5-MBPB and
(R)-5-MBPB produced minimal effects on response rate compared to vehicle control. A repeated
measures ANOVA on response rate indicated no statistically significant effect of (S)-5MBPB [F
(4, 28) = 0.43, P=0.79] or (R)-5-MBPB [F (4, 24) = 0.26, P=0.90] on response rate.

Figure 3. Dose response curves for (S)-5-MBPB, and (R)-5-MBPB. Percent MDMA-Lever
Responses (closed symbols) is plotted on the left Y axis and response rate (open symbols) is
plotted on the right Y axis. Points represent group means (± S.E.M.).
The dose response curves generated from substitution tests with the enantiomers of
6MBPB are displayed in figure 4. Each of these compounds produced a dose-dependent increase
in MDMA-lever responses with full substitution following 1.28 mg/kg. However, differences in
response rate were not statistically significant. The ED50 for (S)-6-MBPB and (R)-6-MBPB
were 0.21and 0.45 (C.I.: 0.31 to 0.61), respectively. Due to the irregular shape of the (S)-6MBPB
dose response function, the lower confidence interval could not be estimated by the nonlinear
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regression model used. Response rates displayed a dose-dependent decrease with both
enantiomers. These effects were not statistically significant for either (S)-6-MBPB [F (4, 28) =
1.09, P=0.38] or (R)-6-MBPB [F (4, 24) = 1.48, P=0.24].

Figure 4. Dose response curves for (S)-6-MBPB, and (R)-6-MBPB. Percent MDMA-Lever
Responses (closed symbols) is plotted on the left Y axis and response rate (open symbols) is
plotted on the right Y axis. Points represent group means (± S.E.M.).

DISCUSSION
Current treatments for PTSD are ineffective for most patients (Shimshoni et al., 2017)
and there is a significant need for new, effective treatments. MDMA-assisted psychotherapy has
shown promise and is under further investigation in clinical trials. The structural similarities
between NPS compounds, such as benzofurans, and MDMA have led to investigations into these
molecules for medication development as potential alternative therapeutics to MDMA. Although
safety and toxicity studies will be required prior to clinical evaluation of benzofurans, preclinical
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studies on their potential efficacy are essential to the medication development process. Toward
that objective, the current study utilized a well-established preclinical behavioral paradigm with
pharmacological specificity. Results from the present study support that benzofuran derivatives
produce similar discriminative stimulus effects to those of MDMA. All tested compounds
produced dose-dependent increases in MDMA-lever responses and substituted fully for the
interoceptive stimulus effects of MDMA at the highest dose administered without disrupting
response rates. Notably, (R)-5-MAPB is more potent than its counterparts ((S)- and (RS)-),
showing full substitution at a lower dose of 0.3 mg/kg, and the (S)- enantiomers of 5-MBPB and
6-MBPB were slightly more potent than their (R)- enantiomers.
This is the first study to examine the discriminative stimulus effects of the enantiomers of
the benzofurans, 5-MAPB, 5-MBPB, and 6-MBPB. Based on past research on racemic 5-MAPB,
the potency differences between (S)- and (R)-5-MAPB observed in the present study, may be
mediated through differential activities at DAT, SERT or NET (Simmler & Liechti, 2018).
Recent investigations on the pharmacological actions of these enantiomers are relevant to the
current study. Specifically, the (S)- enantiomers for all of the benzofuran derivatives assessed in
the current study, were found to be slightly more potent 5-HT releasers compared to the (R)enantiomers [Baumann, personal communication]. Although similar potency differences were
observed in vivo with the 5-MBPB and 6-MBPB enantiomers, this was not observed with the 5MAPB enantiomers. Discrepancies between the current in vivo findings and Baumann’s in vitro
findings could be due to differences in pharmacokinetics (e.g., drug absorption, metabolism) yet
to be evaluated.
The current study findings are supported by previous reports on the neurochemical
similarities between 5-MAPB and MDMA. Fuwa et al. (2016) examined the effects of MDMA,
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5-MAPB, and other benzofuran derivatives in mouse brains and found significant increases in
monoamine levels. 5-MAPB increased monoamine levels significantly more than any other
compound. Notably, at all doses the level of 5-HT was always far greater than DA levels. Fuwa
et al. (2016) attributed the potency of 5-MAPB to its structure: the furan ring found in 5-MAPB
is presumably responsible for increased extracellular monoamine levels compared to the
dioxolane ring in MDMA. Fuwa et al. (2016) also compared monoamine levels following
administration of 5-MAPB and its metabolite, 5-(2-aminopropyl) benzofuran (5-APB). 5-APB
was a significantly more efficacious 5-HT releaser, and the increase in 5-HT was two times
greater than that produced by 5-MAPB.
Although there are no published drug discrimination studies with which to directly
compare the current study findings, Dolan et al. (2017) assessed 5-APB and 6-APDB in rats
trained to discriminate MDMA, methamphetamine, cocaine or 2,5-dimethoxy-4-methylphenyl
isopropylamine (DOM) from saline. They found that 5-APB fully substituted for MDMA and
partially substituted for methamphetamine, cocaine, and DOM. The authors concluded that
5APB discrimination is mediated by both dopamine and serotonin (Dolan et al., 2017). To further
assess the duration of action and active dose range of benzofuran compounds the researchers also
measured the effects of these substances on locomotor activity in mice. Their findings indicated
that 5-APB has a slightly different locomotor activity profile from MDMA, with 5-APB injected
mice showing rapid increases in activity, while MDMA injected rats displayed delayed
stimulation. The current findings are consistent with the conclusions made by both Fuwa et al.
(2016) and Dolan et al. (2017) that 5-MAPB is neurochemically analogous to MDMA.
The observed potency of the (S) isomers of 5- and 6-MBPB closely aligns with the
pharmacological profile of MDMA. With respect to discriminative stimulus effects, (S)-MDMA
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is more potent than (R)-MDMA(Baker & Taylor, 1997 ; Schechter, 1987). In a study in which
animals were trained to discriminate either MDMA enantiomer from saline, the serotonergic
hallucinogens, DOM, lysergic acid diethylamide (LSD), and mescaline partially substituted in
rats trained to discriminate (S)-MDMA, whereas the psychostimulants, amphetamine, and
cocaine did not substitute for either isomer (Baker et al., 1995). In consideration of the
pharmacological specificity of drug discrimination, these findings implicate serotonergic
activities are more salient to the discriminative stimulus effects of (S)-MDMA than to those of
(R)-MDMA, whereas dopaminergic actions are less relevant to the discrimination of either
isomer.
As stated before, Baumann’s in vitro assessment found that for both 5- and 6-MBPB, the
(S)-enantiomer is a more potent 5-HT releaser than the (R)-enantiomer. Additionally, the
(S)enantiomers of these compounds are potent DAT inhibitors and releasers, whereas the
(R)enantiomers are DAT inhibitors, but they are not efficacious DA releasers (Baumann,
personal communication). With the similarities in structure and neurochemical actions of 5MBPB, and 6MBPB to those of MDMA, these benzofuran derivatives are presumably operating
through serotonergic pathways and may produce effects comparable to serotonergic
hallucinogens and less CNS stimulant effects.
The current study was limited to the investigation of selected benzofuran molecules with
structural and pharmacological similarities to MDMA. Thus, other than saline, no negative
controls were assessed in this study. In future studies, assessment of substances with distinct
pharmacological actions, such as ketamine or morphine, to serve as a negative control would add
confidence to the conclusion that the discriminative stimulus effects of benzofurans are mediated
by similar neurochemical actions underlying MDMA’s discriminative stimulus effects.
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Additionally, studies in which rats are trained to discriminate selected benzofuran molecules
would be invaluable to further assessment of these compounds.
In summation, the results obtained from the present study affirm that 5-MAPB, 5-MBPB
and 6-MBPB and their enantiomers produce dose-dependent increases in MDMA-lever
responding and fully substitute for MDMA at the highest dose assessed with minimal effects on
response rate. Further research is needed to discern which monoamine transporters contribute to
the discriminative stimulus effects of these benzofuran derivatives and their enantiomers. For
example, assessment of selective serotonin or dopamine receptor antagonists would help
differentiate the relative importance of DA versus 5-HT in the MDMA-like stimulus effects of
benzofuran derivatives. Based on the structural and pharmacological similarities of MDMA to 5and 6-MBPB, it would also be of interest to assess these compounds for stimulant effects.
Objective assessments of locomotor activity, such as distance traveled and stereotypy measures,
would be valuable to determine if the S- and R- enantiomers differ with respect to CNS stimulant
effects. Nevertheless, the present study contributes to the growing literature on the in vivo
pharmacological actions of benzofuran derivatives. Further evaluation of this class of molecules
is warranted and may aid in development of novel medications that retain MDMA-like
therapeutic effects with reduced toxicities.
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